Join SMI Adviser Clinical Expert Team Members along with APA staff for an overview of the FDA’s Clozapine REMS program, highlighting current research and data from providers and patients, and sharing how APA has been advocating for change.
- History, overview, and myths versus facts about the new REMS
- Some of the current issues with REMS bringing in the prescriber data and NAMI data
- Highlight updates from FDA, including three studies that are in progress
- The wide world of things we could advocate for (from no REMS to changing to an “educational REMS”)